Lentiviral Vectors (LV)
The King’s College London Gene Therapy Vector Facility (GTVF) hosts four MHRA accredited, fully equipped production cleanrooms for GMP vector production. With plans to open further cleanrooms in the next 12-24 months, the facility is purpose-built to handle a high volume of concurrent projects and work to our clients’ timelines.
The team currently makes use of transient production/transfection system for LV production, using adherent cells with multi-layer cell factories. The GTVF has delivered >100 batches of LV and RV over its long history, with the vast majority of its experience being in LV, and has extensive experience with supporting UK, European and US lentiviral vector projects.
Production Process
The GTVF adopts a highly flexible model, enabling us to adapt to client requirements with:
- Vector type
- Client timelines
- Manufacturing process
- Scale
Our adherent, transient transfection, cell factory system enables us to provide enough viral vector for the most ambitious early-stage clinical trials.
End-to-End Project Support
The GTVF takes ownership of all aspects of your viral vector manufacture, including some or all of the following activities:
- Plasmid sourcing (as needed)
- Assay validation and development
- Small-scale R&D grade engineering batches
- Large-scale R&D grade engineering batches
- Large-scale GMP batches
- QC release testing and batch release
- Regulatory support
- Project Management
Scale
Our adherent, transient transfection, cell factory system enables us to provide enough viral vector for the most ambitious early-stage clinical trials.
More Information
For more detail on licenses, plasmid sourcing, QC release testing and tech transfer, please see ‘Our Services’ page.
Production and development services also available:
Get In Touch
Contact us to discuss your lentiviral vector, retroviral vector, and adeno-associated viral vector GMP manufacturing needs: